MCID: MLD018
MIFTS: 48

Mild Cognitive Impairment

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Mild Cognitive Impairment

MalaCards integrated aliases for Mild Cognitive Impairment:

Name: Mild Cognitive Impairment 12 74 42

Classifications:



External Ids:

Disease Ontology 12 DOID:0080832

Summaries for Mild Cognitive Impairment

MedlinePlus : 42 Some forgetfulness can be a normal part of aging. However, some people have more memory problems than other people their age. This condition is called mild cognitive impairment, or MCI. People with MCI can take care of themselves and do their normal activities. MCI memory problems may include Losing things often Forgetting to go to events and appointments Having more trouble coming up with words than other people of the same age Memory problems can also have other causes, including certain medicines and diseases that affect the blood vessels that supply the brain. Some of the problems brought on by these conditions can be managed or reversed. Your health care provider can do thinking, memory, and language tests to see if you have MCI. You may also need to see a specialist for more tests. Because MCI may be an early sign of Alzheimer's disease, it's really important to see your health care provider every 6 to 12 months. At this time, there is no proven drug treatment for MCI. Your health care provider can check to see if you have any changes in your memory or thinking skills over time. NIH: National Institute on Aging

MalaCards based summary : Mild Cognitive Impairment is related to subjective cognitive decline and movement disease. An important gene associated with Mild Cognitive Impairment is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Pathways of neurodegeneration - multiple diseases and Alzheimers Disease. The drugs Rivastigmine and Atropine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and temporal lobe, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A cognitive disorder that is characterized by objective impairment in cognition with minimal impairment of their capacity to undertake the instrumental activities of daily living.

Wikipedia : 74 Mild cognitive impairment (MCI) is a neurocognitive disorder which involves cognitive impairments beyond... more...

Related Diseases for Mild Cognitive Impairment

Diseases related to Mild Cognitive Impairment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 413)
# Related Disease Score Top Affiliating Genes
1 subjective cognitive decline 31.7 MAPT BDNF APOE
2 movement disease 31.0 MAPT BDNF APP APOE
3 rem sleep behavior disorder 31.0 MAPT BCHE APOE
4 cerebrovascular disease 31.0 MTHFR MAPT APP APOE ACE
5 semantic dementia 31.0 MAPT APOE
6 sleep apnea 30.9 BDNF APOE ACE
7 traumatic brain injury 30.8 COMT BDNF APOE
8 amnestic disorder 30.8 MAPT CHAT BDNF BCHE APP APOE
9 anterograde amnesia 30.7 BDNF APOE
10 agraphia 30.7 MAPT APOE
11 aphasia 30.7 MAPT BDNF APP APOE
12 posterior cortical atrophy 30.6 MAPT APOE
13 vascular disease 30.6 SOD1 MTHFR CST3 APOE ACE
14 alzheimer disease 10 30.6 MAPT APOE
15 nominal aphasia 30.6 MAPT APOE
16 essential tremor 30.5 MAPT COMT BDNF
17 carotid stenosis 30.5 MTHFR APOE ACE
18 major depressive disorder 30.5 MTHFR COMT BDNF APOE
19 head injury 30.5 SOD1 CHAT APOE
20 anxiety 30.5 COMT BDNF APP APOE ACE
21 brain injury 30.5 MAPT COMT BDNF APOE
22 binswanger's disease 30.4 MAPT APP APOE
23 arteriolosclerosis 30.4 MAPT APP APOE
24 frontotemporal dementia 30.4 SORL1 SOD1 MAPT BCHE APP APOE
25 simultanagnosia 30.4 MAPT APOE
26 alzheimer's disease 1 30.4 APP APOE
27 sleep disorder 30.2 MAPT COMT BDNF BCHE APOE ACE
28 alzheimer disease 2 30.2 MAPT APP APOE
29 generalized atherosclerosis 30.2 APOE ACE
30 alcohol use disorder 30.2 MTHFR COMT BDNF
31 basal ganglia calcification 30.2 MAPT APP APOE
32 dementia 30.1 SORL1 MAPT LRP1 CST3 COMT CHAT
33 hydrocephalus 30.0 MTHFR MAPT BDNF APP APOE ACE
34 alzheimer disease 7 30.0 SOD1 MAPT APOE
35 early-onset, autosomal dominant alzheimer disease 29.9 SORL1 MAPT APP APOE
36 amyloidosis 29.9 MAPT CST3 CLU BACE1 APP APOE
37 bipolar disorder 29.9 MTHFR MAPT COMT BDNF APP APOE
38 huntington disease 29.9 SOD1 MAPT CHAT BDNF APP
39 homocysteinemia 29.8 MTHFR CST3 COMT CLU APOE
40 ischemia 29.8 SOD1 BDNF APP ACE
41 attention deficit-hyperactivity disorder 29.8 MTHFR COMT BDNF BCHE ADRA2B
42 down syndrome 29.8 SOD1 MTHFR MAPT CHAT BACE1 APP
43 lipoprotein quantitative trait locus 29.8 MTHFR CST3 CLU APOE ACE
44 vascular dementia 29.8 SOD1 MTHFR MAPT CST3 CHAT BCHE
45 cerebral palsy 29.7 SOD1 MTHFR BDNF APOE
46 chronic kidney disease 29.7 SOD1 MTHFR CST3 APOE ACE
47 supranuclear palsy, progressive, 1 29.7 SOD1 MAPT CHAT BCHE BACE1 APP
48 body mass index quantitative trait locus 11 29.7 LRP1 COMT BDNF BCHE APOE ACE
49 substance abuse 29.6 COMT BDNF BCHE ACE
50 stroke, ischemic 29.6 MTHFR MAPT CST3 BDNF BACE1 APOE

Graphical network of the top 20 diseases related to Mild Cognitive Impairment:



Diseases related to Mild Cognitive Impairment

Symptoms & Phenotypes for Mild Cognitive Impairment

MGI Mouse Phenotypes related to Mild Cognitive Impairment:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ACE ADRA2B APOE APP BACE1 BCHE
2 behavior/neurological MP:0005386 10.29 ACE ADRA2B APOE APP BACE1 BDNF
3 cardiovascular system MP:0005385 10.23 ACE ADRA2B APOE APP CHAT CLU
4 growth/size/body region MP:0005378 10.21 ACE ADRA2B APOE APP BACE1 BDNF
5 mortality/aging MP:0010768 10.18 ACE ADRA2B APOE APP BACE1 BCHE
6 nervous system MP:0003631 10.1 ACE APOE APP BACE1 BDNF CHAT
7 muscle MP:0005369 10.06 ADRA2B APOE APP BACE1 CHAT CLU
8 reproductive system MP:0005389 9.77 ACE ADRA2B APOE APP BCHE BDNF
9 no phenotypic analysis MP:0003012 9.63 APOE APP BACE1 BDNF MAPT MTHFR
10 vision/eye MP:0005391 9.23 ACE APOE BDNF CHAT MAPT MTHFR

Drugs & Therapeutics for Mild Cognitive Impairment

Drugs for Mild Cognitive Impairment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
2
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
3
Donepezil Approved Phase 4 120014-06-4 3152
4
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
5
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
6
Rasagiline Approved Phase 4 136236-51-6 3052776
7
Lithium carbonate Approved Phase 4 554-13-2
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
10
Simvastatin Approved Phase 4 79902-63-9 54454
11
Iodine Approved, Investigational Phase 4 7553-56-2 807
12
Levetiracetam Approved Phase 4 102767-28-2 441341
13
Memantine Approved, Investigational Phase 4 19982-08-2 4054
14
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
15
Amitriptyline Approved Phase 4 50-48-6 2160
16 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
17
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
18
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
21
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
22
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
23
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
24
Topiramate Approved Phase 4 97240-79-4 5284627
25
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
26
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
27
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
28
Propranolol Approved, Investigational Phase 4 525-66-6 4946
29
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
30
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
31
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
32
Huperzine A Approved, Experimental Phase 4 102518-79-6
33
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
34
Cadexomer iodine Experimental Phase 4 94820-09-4
35
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
36
Corticosterone Experimental Phase 4 50-22-6 5753
37 Protective Agents Phase 4
38 Neuroprotective Agents Phase 4
39 Atomoxetine Hydrochloride Phase 4
40 Adrenergic Agents Phase 4
41 Cholinesterase Inhibitors Phase 4
42 Cholinergic Agents Phase 4
43 Antiparkinson Agents Phase 4
44 Excitatory Amino Acid Antagonists Phase 4
45 Parasympatholytics Phase 4
46 Anti-Asthmatic Agents Phase 4
47 Ophthalmic Solutions Phase 4
48 Cholinergic Antagonists Phase 4
49 Mydriatics Phase 4
50 Muscarinic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 664)
# Name Status NCT ID Phase Drugs
1 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
2 The Safety and Efficacy of 1612 Capsules in Treatment of aMnestic Mild Cognitive Impairment: a 52-week, Double Blind,Randomized, Parallel,Placebo Controlled Trial. Unknown status NCT02982642 Phase 4 1612 capsule;Placebos
3 Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
4 Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study Completed NCT01340885 Phase 4 Strattera;Exelon
5 Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment Completed NCT00446485 Phase 4 Ginkgo biloba standardized extract 24/6;Ginkgo Biloba standardized extract 24/6;placebo
6 Olfactory Deficits in Mild Cognitive Impairment as a Predictor of Improved Cognition on Donepezil Completed NCT01845636 Phase 4 Donepezil;Atropine
7 Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI: a Randomized, Double-blind, Placebo-controlled Exploratory Study Completed NCT01046292 Phase 4 Ginkgo biloba
8 The Depression and Memory Trial Completed NCT02590874 Phase 4 Duloxetine;Placebo
9 Effects of Vildagliptin, a DPP-4 Inhibitor, in Elderly Diabetic Patients With Mild Cognitive Impairment Completed NCT03819127 Phase 4 Vildagliptin 50 MG Oral Tablet;Metformin Pill
10 The Efficacy and Safety of Qinggongshoutao Bolus for aMnestic Mild Cognitive Impairment: A 52- Week Randomized, Double-blind, Controlled,Three Arms, Multi-center Study Completed NCT02982603 Phase 4 Qinggongshoutao Bolus;Ginkgo Biloba Extract 761;Placebos
11 A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment Completed NCT00934375 Phase 4 Aricept (donepezil hydrochloride);placebo
12 Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age Completed NCT01902004 Phase 4 Escitalopram;Memantine;Placebo
13 A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study Completed NCT01126424 Phase 4 Solifenacin;Oxybutynin;Placebo
14 A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI) Completed NCT00293176 Phase 4 Donepezil Hydrochloride;Placebo
15 A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy Completed NCT01497652 Phase 4 Rasagiline/Placebo;Rasagiline
16 A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease Completed NCT01519271 Phase 4 Exelon Patch (rivastigmine transdermal system);Placebo Patches
17 Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression Completed NCT01658228 Phase 4 Donepezil;Placebo;Citalopram;Venlafaxine
18 Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer Recruiting NCT03016741 Phase 4 Prednisone;Abiraterone Acetate;Enzalutamide
19 Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease Recruiting NCT04346862 Phase 4 Acetyl-L-carnitine hydrochloride 500mg;Placebo
20 Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia Recruiting NCT03185208 Phase 4 Lithium Carbonate;Placebo oral capsule
21 A Pilot, Multiple Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Use of Methylphenidate for Cognitive and Behavioral Symptoms in Mild Cognitive Impairment and Dementia Recruiting NCT03811847 Phase 4 Methylphenidate Extended Release Oral Capsule
22 Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients Active, not recruiting NCT00842920 Phase 4 Simvastatin 60 mg;Placebo;Simvastatin 20 mg
23 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
24 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
25 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
26 Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Not yet recruiting NCT02931136 Phase 4 Huperzine A;Placebo
27 Water-based Activity to Enhance Recall in Veterans: A Randomized Clinical Trial Not yet recruiting NCT04296565 Phase 4
28 Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Not yet recruiting NCT04522739 Phase 4 Spironolactone;Placebo
29 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
30 DIetary Supplements, Executive funcTions and Vitamin D (DIET-D): a Double-blind Randomized Controlled Trial Unknown status NCT01708005 Phase 2, Phase 3 Lecitone®Se-Vitamin D3;Placebo
31 Randomized Double Blind Levothyroxine vs Placebo, Mind (NEUROPSI) Improvement in Elderly With Persistent TSH 4-10 mUI/L Completed NCT00921050 Phase 2, Phase 3 levothyroxine sodium;excipient without levothyroxine (placebo)
32 Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment Completed NCT01299766 Phase 3
33 Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment Completed NCT01876823 Phase 2, Phase 3 es-citalopram;Memantine
34 A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed NCT01028053 Phase 3 Flutemetamol (18F) Injection
35 Phase III Study of Shenwu Capsule in Treating Amnestic Mild Cognitive Impairment Completed NCT01451749 Phase 3 Shenwu Capsule;Donepezil
36 Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD) Completed NCT01767909 Phase 2, Phase 3 Insulin (Humulin® R U-100);Placebo
37 Enhancing Memory Functions in Patients With Mild Cognitive Impairment by Dietary Interventions and in Combination With Exercise and Cognitive Training - Proof of Concept and Mechanisms Completed NCT01219244 Phase 2, Phase 3
38 Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke Completed NCT03815292 Phase 3 MMH-MAP;Placebo
39 An Open-label, Controlled, Cross-over Trial of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) in Mild Cognitive Impairment Completed NCT01688128 Phase 3
40 Effects of Multimodal Cognitive Enhancement Therapy (MCET) for People With Mild Cognitive Impairment and Early Stage Dementia: a Randomized, Controlled, Double-blind, Cross-over Trial Completed NCT02350738 Phase 3
41 Testosterone Supplementation in Men With MCI Completed NCT00539305 Phase 3 testosterone gel;placebo gel
42 An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment Completed NCT00240695 Phase 3 galantamine hydrobromide
43 A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease. Completed NCT00236574 Phase 3 Galantamine hydrobromide
44 A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD) Completed NCT00000173 Phase 3 Donepezil;Vitamin E
45 An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease Completed NCT02016560 Phase 2, Phase 3 florbetapir F 18;Flortaucipir F18
46 A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease Completed NCT00236431 Phase 3 Galantamine hydrobromide
47 An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Completed NCT01662882 Phase 2, Phase 3 florbetapir (18F)
48 MRI and PET Biomarkers for Cognitive Decline in Older Adults Recruiting NCT03860857 Phase 3 Tau PET scan using MK-6240
49 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease Recruiting NCT03486938 Phase 2, Phase 3 Placebo Oral Tablet;AGB101 220 mg tablet
50 Exercise Training to Improve Cognitive Function Recruiting NCT03824639 Phase 3

Search NIH Clinical Center for Mild Cognitive Impairment

Genetic Tests for Mild Cognitive Impairment

Anatomical Context for Mild Cognitive Impairment

MalaCards organs/tissues related to Mild Cognitive Impairment:

40
Brain, Cortex, Temporal Lobe, Eye, Heart, Cingulate Cortex, Prefrontal Cortex

Publications for Mild Cognitive Impairment

Articles related to Mild Cognitive Impairment:

(show top 50) (show all 17632)
# Title Authors PMID Year
1
Direct and indirect neurological, cognitive, and behavioral effects of COVID-19 on the healthy elderly, mild-cognitive-impairment, and Alzheimer's disease populations. 42 61
33409824 2021
2
Efficacy and safety of Hominis placenta pharmacopuncture on mild cognitive impairment: Randomized, double blind, placebo-controlled, multi-center trial. 42 61
33181659 2020
3
Therapeutic Efficacy of Plasmalogens for Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer's Disease. 61 42
33417216 2020
4
Predictive models for mild cognitive impairment to Alzheimer's disease conversion. 61
33510068 2021
5
Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer's disease: new biomarkers for diagnosis and disease progression? 61
33318425 2021
6
Improving wellbeing of community-dwelling people with mild cognitive impairment: the SENIOR (SystEm of Nudge theory based ICT applications for OldeR citizens) project. 61
33229736 2021
7
Characterization of prospective memory in mild cognitive impairment by using the Ecological test of Prospective Memory. 61
32487003 2021
8
Neuroimaging mechanisms of high-frequency repetitive transcranial magnetic stimulation for treatment of amnestic mild cognitive impairment: a double-blind randomized sham-controlled trial. 61
33063732 2021
9
Characterising spoken responses to an intelligent virtual agent by persons with mild cognitive impairment. 61
32552087 2021
10
Exercise for the prevention and treatment of neurocognitive disorders: new evidence and clinical recommendations. 61
33470667 2021
11
Combined physical and cognitive training for older adults with and without cognitive impairment: A systematic review and network meta-analysis of randomized controlled trials. 61
33249177 2021
12
Physical Exercise Interventions Targeting Cognitive Functioning and the Cognitive Domains in Nondementia Samples: A Systematic Review of Meta-Analyses. 61
32295450 2021
13
Preserving and enhancing social health in neurocognitive disorders. 61
33395096 2021
14
The Utility of Cognitive Screeners in the Detection of Dementia Spectrum Disorders in Spanish-Speaking Populations. 61
32314661 2021
15
The Association between Cerebral Small Vessel Disease and the Gut Microbiome: A Cross-Sectional Analysis. 61
33423868 2021
16
Disabilities of the arms, pinch strength, and mild cognitive impairment in patients with coronary artery disease. 61
33121796 2021
17
The utility of olfactory function in distinguishing early-stage Alzheimer's disease from HIV-associated neurocognitive disorders. 61
33252483 2021
18
Preventive and Therapeutic Strategies in Alzheimer's Disease: Focus on Oxidative Stress, Redox Metals, and Ferroptosis. 61
32486897 2021
19
Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age. 61
32882319 2021
20
Polymorphism rs11867353 of Tyrosine Kinase Non-Receptor 1 (TNK1) Gene Is a Novel Genetic Marker for Alzheimer's Disease. 61
33070267 2021
21
PET/CT for Brain Amyloid: A Feasibility Study for Scan Time Reduction by Deep Learning. 61
33512838 2021
22
A study of regional homogeneity of resting-state Functional Magnetic Resonance Imaging in mild cognitive impairment. 61
33417993 2021
23
Maximal aerobic capacity is associated with hippocampal cognitive reserve in older adults with amnestic mild cognitive impairment. 61
33314497 2021
24
Driving exposure, patterns and safety critical events for older drivers with and without mild cognitive impairment: Findings from a naturalistic driving study. 61
33429206 2021
25
Procedural Learning in Individuals with Amnestic Mild Cognitive Impairment and Alzheimer's Dementia: a Systematic Review and Meta-analysis. 61
32897482 2021
26
Prevalence of obstructive sleep apnea at an outpatient memory clinic. 61
33474502 2021
27
Preventing dementia? Interventional approaches in mild cognitive impairment. 61
33440197 2021
28
Quantitative Assessment of Resting-State for Mild Cognitive Impairment Detection: A Functional Near-Infrared Spectroscopy and Deep Learning Approach. 61
33579839 2021
29
Strategies for the use of Ginkgo biloba extract, EGb 761® , in the treatment and management of mild cognitive impairment in Asia: Expert consensus. 61
33352000 2021
30
[Linguistic impairments in patients with mild cognitive impairment: a systematic review]. 61
33506484 2021
31
Digital Dementia Registry Bavaria-digiDEM Bayern: study protocol for a multicentre, prospective, longitudinal register study. 61
33558357 2021
32
Relationship between cerebral atrophy and number of present teeth in elderly individuals with cognitive decline. 61
33285222 2021
33
Association between positive grandparental involvement during childhood and generativity in late life among community-dwelling, cognitively intact, older adults in Japan. 61
33559380 2021
34
A Comprehensive Meta-analysis on Short-term and Working Memory Dysfunction in Parkinson's Disease. 61
33523408 2021
35
Effect of self-imagination on memory for older adults and aMCI patients. 61
33530871 2021
36
Urinary kynurenine as a biomarker for Parkinson's disease. 61
32661882 2021
37
Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. 61
32734458 2021
38
Nicotinic receptor modulation of the default mode network. 61
33216167 2021
39
Protein Kinase C-Gamma Knockout Mice Show Impaired Hippocampal Short-Term Memory While Preserved Long-Term Memory. 61
32996086 2021
40
Digital trail making test-black and white: Normal vs MCI. 61
33529537 2021
41
TraMiner: Vision-Based Analysis of Locomotion Traces for Cognitive Assessment in Smart-Homes. 61
33552305 2021
42
Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study. 61
32865628 2021
43
Dendritic Spine Remodeling and Synaptic Tau Levels in PS19 Tauopathy Mice. 61
33346120 2021
44
[The Impact of Family-Centered Advance Care Planning for Persons With Dementia and Family Caregivers on Decision-Making Conflicts in End-of-Life Care]. 61
33521917 2021
45
Subtemporal, Transapical, and Transcavernous Approach to Clip Low-Lying Basilar Tip Aneurysm: 2-Dimensional Operative Video. 61
33548927 2021
46
Functional outcome after critical illness in older patients: a population-based study. 61
33012281 2021
47
Quantitative Susceptibility Mapping of Brain Iron and β-Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults. 61
33231528 2021
48
Are auditory processing and cognitive performance assessments overlapping or distinct? Parsing the auditory behaviour of older adults. 61
32701036 2021
49
Hippocampal subregional volume changes in elders classified using positron emission tomography-based Alzheimer's biomarkers of β-amyloid deposition and neurodegeneration. 61
33073383 2021
50
A New dispersion entropy and fuzzy logic system methodology for automated classification of dementia stages using electroencephalograms. 61
33383465 2021

Variations for Mild Cognitive Impairment

Expression for Mild Cognitive Impairment

Search GEO for disease gene expression data for Mild Cognitive Impairment.

Pathways for Mild Cognitive Impairment

GO Terms for Mild Cognitive Impairment

Cellular components related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.28 SORL1 SOD1 MAPT LRP1 CST3 COMT
2 extracellular exosome GO:0070062 10.11 SORL1 SOD1 CST3 COMT CLU APP
3 Golgi apparatus GO:0005794 10.02 SORL1 LRP1 CST3 CLU BACE1 APP
4 cytoplasmic vesicle GO:0031410 9.97 SORL1 SOD1 CLU BACE1 APP
5 endosome GO:0005768 9.95 SORL1 LRP1 BACE1 APP ACE
6 cell surface GO:0009986 9.92 SORL1 CLU BACE1 APP ADRA2B
7 extracellular space GO:0005615 9.91 SORL1 SOD1 CST3 CLU BDNF BCHE
8 extracellular region GO:0005576 9.85 SORL1 SOD1 MAPT CST3 CLU BDNF
9 axon GO:0030424 9.83 MAPT COMT BDNF BACE1 APP
10 neuronal cell body GO:0043025 9.8 SOD1 MAPT LRP1 BACE1 APOE
11 endoplasmic reticulum lumen GO:0005788 9.77 CST3 BCHE BACE1 APP APOE
12 recycling endosome GO:0055037 9.73 SORL1 BACE1 APP
13 early endosome GO:0005769 9.72 SORL1 LRP1 BACE1 APP APOE
14 main axon GO:0044304 9.49 MAPT APP
15 neurofibrillary tangle GO:0097418 9.46 MAPT CLU
16 dendrite GO:0030425 9.43 MAPT LRP1 COMT BDNF BACE1 APOE
17 nuclear envelope lumen GO:0005641 8.8 SORL1 BCHE APP

Biological processes related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.91 MAPT APP APOE ACE
2 response to drug GO:0042493 9.89 SOD1 MTHFR COMT BCHE
3 neuron projection development GO:0031175 9.84 MAPT APP APOE
4 positive regulation of neuron projection development GO:0010976 9.83 LRP1 BDNF APOE
5 response to oxidative stress GO:0006979 9.82 SOD1 APP APOE
6 platelet degranulation GO:0002576 9.81 SOD1 CLU APP
7 positive regulation of protein binding GO:0032092 9.71 LRP1 APP ACE
8 learning GO:0007612 9.69 COMT BCHE APP
9 negative regulation of neuron apoptotic process GO:0043524 9.67 SOD1 LRP1 BDNF APOE
10 positive regulation of cholesterol efflux GO:0010875 9.66 LRP1 APOE
11 positive regulation of superoxide anion generation GO:0032930 9.65 SOD1 MAPT
12 response to reactive oxygen species GO:0000302 9.65 SOD1 APOE
13 reverse cholesterol transport GO:0043691 9.63 CLU APOE
14 heart contraction GO:0060047 9.63 SOD1 ACE
15 cellular response to amyloid-beta GO:1904646 9.63 LRP1 BACE1 APP
16 astrocyte activation GO:0048143 9.62 MAPT APP
17 amyloid-beta metabolic process GO:0050435 9.62 BACE1 ACE
18 negative regulation of long-term synaptic potentiation GO:1900272 9.61 APP APOE
19 supramolecular fiber organization GO:0097435 9.6 MAPT CST3
20 amyloid fibril formation GO:1990000 9.58 MAPT APP
21 negative regulation of amyloid fibril formation GO:1905907 9.58 CLU APOE
22 cellular response to manganese ion GO:0071287 9.57 BACE1 APP
23 response to folic acid GO:0051593 9.56 MTHFR BCHE
24 negative regulation of cholesterol biosynthetic process GO:0045541 9.55 SOD1 APOE
25 positive regulation of amyloid-beta clearance GO:1900223 9.52 LRP1 APOE
26 negative regulation of amyloid-beta formation GO:1902430 9.5 SORL1 CLU APOE
27 protein import GO:0017038 9.49 CLU APOE
28 regulation of smooth muscle cell migration GO:0014910 9.48 SORL1 ACE
29 astrocyte activation involved in immune response GO:0002265 9.43 LRP1 APP
30 microglial cell activation GO:0001774 9.43 MAPT CLU APP
31 regulation of amyloid-beta clearance GO:1900221 9.4 CLU APOE
32 cellular protein metabolic process GO:0044267 9.35 SORL1 CST3 BACE1 APP APOE
33 response to lead ion GO:0010288 9.33 MAPT BACE1 APP
34 positive regulation of amyloid fibril formation GO:1905908 8.8 CLU APP APOE

Molecular functions related to Mild Cognitive Impairment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.73 CLU BDNF APP APOE
2 chaperone binding GO:0051087 9.43 SOD1 MAPT CLU
3 heparan sulfate proteoglycan binding GO:0043395 9.4 LRP1 APOE
4 apolipoprotein binding GO:0034185 9.37 MAPT LRP1
5 enzyme binding GO:0019899 9.35 SOD1 MAPT BCHE BACE1 APP
6 low-density lipoprotein particle receptor activity GO:0005041 9.32 SORL1 LRP1
7 amyloid-beta binding GO:0001540 9.17 SORL1 LRP1 CST3 CLU BCHE BACE1
8 lipoprotein particle binding GO:0071813 9.16 MAPT APOE

Sources for Mild Cognitive Impairment

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....